Pressmeddelande -
The Corline Heparin Conjugate may help in vascular repair
Swedish company Corline Systems AB, maker and distributor of a proprietary and unique heparin coating technology for use in Regenerative Medicine, has been the focus of a scientific presentation at the 5th annual meeting of the Scandinavian Society for Biomaterials that was held in Uppsala, Sweden, May 2012.
Researchers from the Uppsala University presented preliminary results from an on-going project showing that the Corline Heparin Conjugate, CHC, may play an important role in vascular repair.
“We are very pleased with the data presented by the outstanding researchers at the Uppsala University. Clearly, scientific evidence of this quality is important to support our continuing development of new applications and partnerships in the regenerative medicine industry. We are continuously striving to leverage our technology to the benefit of patients in need, and the scientific collaborations are one important tool to achieving this goal.”, comments CEO Henrik Nittmar.
The research group shows that CHC can self-assemble and anchor to the vascular injury site, and that CHC is able to reduce thrombogenicity and reduce platelet adhesion at the site. In addition, when stimulated with growth factors (VEGF), CHC enhances proliferation of endothelial cells at the site of injury. These critical functions make CHC an interesting candidate for the treatment of damaged vasculature[1].
Corline is developing its technology for use in a multitude of clinical applications in the Regenerative Medicine space, both in partnership with industrial companies from different corners of the world, and together with international research groups in Europe, the US and Australia. A common denominator is that all projects use the same core technology, the CHC.
“We are investing heavily to develop new applications for our technology in Regenerative Medicine. Repairing vascular injury may well prove to be one of the key application areas for the future. It has that kind of potential.”, concludes CEO Henrik Nittmar.
--------------------------------------------------------------------
[1] Nordling et al. ”Vascular repair by anchoring of a macromolecular heparin conjugate (Paper presented at Scandinavian Society for Biomaterials, Uppsala, May 2012)
Ämnen
- Hälsa, sjukvård, läkemedel
Kategorier
- corline heparin surface
- life science
- regenerative medicine
- tissue engineering
- innovation
- heparin
- bioscaffolds
- transplantation
About Corline and CHS
Corline is a biotechnology company based in Uppsala, Sweden, that develops, manufactures and distributes a proprietary patent protected heparin conjugate surface (CHS) that can be used both for medical devices and for Regenerative Medicine (cell therapy and tissue engineering). In 2011 the market for Regenerative Medicine totaled a 3.6 bn USD turnover, with a 80 % share being focused in the US.
CHS can be used to coat living cells and tissue without compromising their biological functions. CHS helps attenuate the local inflammation that is formed on and around grafts at transplantation, and promotes new blood vessels to grow more quickly to support the graft. For the patient, CHS potentially means better clinical outcome and a more rapid recovery from treatment.
Corline conducts pre-clinical and clinical studies within a number of cell and tissue therapy areas. These studies are a first step towards realizing the company’s vision of having its CHS platform technology widely used within the future Regenerative Medicine market. The CHS technology is protected by more than 20 granted and pending patents.
Corline is a privately held company, financially backed by members of the Crafoord family, primarily known for the development of Swedish medical device company Gambro (founded by Holger Crafoord), and Lars Sunnanväder, a well-known entrepreneur who has founded several medical device and biotechnology companies, e.g. heart/lung assist and coronary surgical device manufacturer Jostra, lung assist device manufacturer Novalung, Jotec, Jolife, Joline and other companies within this field.
For more information, please contact:
Henrik Nittmar, CEO
Tel. +46 (0)18 71 30 90
henrik.nittmar@corline.se
